What is HC Wainwright's Forecast for STOK FY2029 Earnings?

Key Points

• HC Wainwright lowered its FY2029 EPS forecast for Stoke Therapeutics to $1.51, down from $1.55, while forecasting FY2030 EPS of $3.48.
• Stoke reported a quarterly loss of $1.08 per share, missing the $0.93 consensus estimate, although revenue of $11.26 million exceeded expectations of $8.21 million.
• Analyst sentiment remains broadly positive, with a “Moderate Buy” consensus rating, 10 Buy ratings, one Sell rating, and an average price target of $44.17.

Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Stock analysts at HC Wainwright decreased their FY2029 earnings estimates for shares of Stoke Therapeutics in a research report issued to clients and investors on Monday, November 2nd. HC Wainwright analyst A. Ghosh now forecasts that the company will earn $1.51 per share for the year, down from their previous estimate of $1.55. The consensus estimate for Stoke Therapeutics' current full-year earnings is ($3.52) per share. HC Wainwright also issued estimates for Stoke Therapeutics' FY2030 earnings at $3.48 EPS.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last released its earnings results on Thursday, October 29th. The company reported ($1.08) earnings per share for the quarter, missing analysts' consensus estimates of ($0.93) by ($0.15). The business had revenue of $11.26 million during the quarter, compared to analysts' expectations of $8.21 million. Stoke Therapeutics had a negative return on equity of 59.36% and a negative net margin of 753.60%.

A number of other equities analysts have also weighed in on STOK. The Goldman Sachs Group reissued a "buy" rating and set a $43.00 price objective on shares of Stoke Therapeutics in a research note on Friday. Weiss Ratings reaffirmed a "sell (d)" rating on shares of Stoke Therapeutics in a research note on Friday, August 7th. Canaccord Genuity Group reduced their price target on Stoke Therapeutics from $60.00 to $58.00 and set a "buy" rating on the stock in a report on Tuesday, August 4th. Chardan Capital reissued a "buy" rating and set a $35.00 price target on shares of Stoke Therapeutics in a research report on Tuesday, August 4th. Finally, Wedbush upped their price objective on shares of Stoke Therapeutics from $38.00 to $40.00 and gave the company an "outperform" rating in a report on Tuesday, August 4th. Ten investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $44.17.

Stoke Therapeutics Stock Performance

STOK stock opened at $26.48 on Tuesday. The business has a 50 day simple moving average of $27.31 and a 200-day simple moving average of $30.87. Stoke Therapeutics has a 1 year low of $20.32 and a 1 year high of $40.22.

Institutional Trading of Stoke Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Quantbot Technologies LP purchased a new position in shares of Stoke Therapeutics in the 2nd quarter valued at about $34,000. KBC Group NV purchased a new stake in Stoke Therapeutics during the first quarter worth approximately $36,000. Sterling Capital Management LLC boosted its holdings in Stoke Therapeutics by 849.7% in the third quarter. Sterling Capital Management LLC now owns 1,833 shares of the company's stock valued at $48,000 after purchasing an additional 1,640 shares in the last quarter. Western Wealth Management LLC acquired a new position in Stoke Therapeutics in the first quarter valued at approximately $55,000. Finally, EverSource Wealth Advisors LLC increased its stake in Stoke Therapeutics by 195.3% in the first quarter. EverSource Wealth Advisors LLC now owns 1,837 shares of the company's stock valued at $60,000 after purchasing an additional 1,215 shares during the last quarter.

Insider Transactions at Stoke Therapeutics

In related news, General Counsel Jonathan Allan sold 2,861 shares of the business's stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $32.03, for a total transaction of $91,637.83. Following the completion of the transaction, the general counsel directly owned 21,225 shares of the company's stock, valued at $679,836.75. The trade was a 11.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Edward M. Md Kaye sold 12,567 shares of the company's stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $32.03, for a total value of $402,521.01. Following the sale, the director owned 124,557 shares in the company, valued at approximately $3,989,560.71. This trade represents a 9.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 27,418 shares of company stock worth $860,914 over the last ninety days. Company insiders own 9.60% of the company's stock.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc is a clinical-stage biotechnology company focused on developing genetic medicines for severe diseases caused by insufficient protein production. The company uses its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform to design antisense oligonucleotides that can increase the expression of specific genes and potentially address the underlying causes of genetic disorders.

Stoke's leading product candidate is STK-001, an investigational antisense oligonucleotide being developed for the treatment of Dravet syndrome, a severe genetic epilepsy most commonly associated with mutations in the SCN1A gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.